Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Travere Therapeutics Inc
(NQ:
TVTX
)
12.03
-0.21 (-1.72%)
Streaming Delayed Price
Updated: 10:37 AM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
154,480
Open
12.12
Bid (Size)
12.03 (1)
Ask (Size)
12.06 (1)
Prev. Close
12.24
Today's Range
11.89 - 12.38
52wk Range
5.120 - 14.07
Shares Outstanding
60,717,176
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
September 10, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
This United States Steel Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
September 09, 2024
Via
Benzinga
Performance
YTD
+25.84%
+25.84%
1 Month
+37.49%
+37.49%
3 Month
+63.90%
+63.90%
6 Month
+47.61%
+47.61%
1 Year
-12.89%
-12.89%
More News
Read More
Analyst Ratings For Travere Therapeutics
September 06, 2024
Via
Benzinga
Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday
September 06, 2024
Via
Benzinga
Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease
September 06, 2024
Via
Investor's Business Daily
Expert Ratings For Travere Therapeutics
August 02, 2024
Via
Benzinga
Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analysts
May 07, 2024
Via
Benzinga
NIO To Rally Around 65%? Here Are 10 Top Analyst Forecasts For Friday
September 06, 2024
Via
Benzinga
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
September 05, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
August 22, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
August 06, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024
August 02, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Travere Therapeutics Reports Second Quarter 2024 Financial Results
August 01, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
July 27, 2024
Via
Talk Markets
Travere Therapeutics to Report Second Quarter 2024 Financial Results
July 25, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
July 10, 2024
Via
Benzinga
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
July 09, 2024
Via
Benzinga
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
July 08, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 11, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
May 09, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
May 08, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
TVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024
May 06, 2024
Via
InvestorPlace
Travere Therapeutics Reports First Quarter 2024 Financial Results
May 06, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Report First Quarter 2024 Financial Results
April 29, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.